# US 2009/0275533 A1 · Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275533 A1
- Document ID: US20090275533A1
- Status: Published application
- Kind: A1
- Application number: 12/428,044
- Filed: 2009-04-22
- Published: 2009-11-05
- Earliest claimed: 2008-04-30
- Assignees: National Health Research Institutes
- Inventors: Hsing-Pang Hsieh; Selvaraj Mohane Coumar; Tsu-An Hsu; Su-Ying Wu; Yu-Sheng Chao
- Web page: https://patentgrep.com/patent/US20090275533A1

## CPC

- C07F 7/0812: {comprising a heterocyclic ring}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/70: condensed with carbocyclic rings or ring systems
- C07D 413/14: containing three or more hetero rings
- C07D 487/02: in which the condensed system contains two hetero rings
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Fused bicyclic pyrimidine compounds of formula (I): wherein R1, R3, R4, X1, X2, Y, Z, A, B, C, D, n, and the two bonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds.

## Claims

### Claim 1

A compound of formula (I):
wherein
one of the two bonds is a single bond and the other is a double bond;
X1 is O or NRa and X2 is CR2, or X1 is CR2 and X2 is O or NRa, in which Ra is H, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
each of Y and Z, independently, is O, S, or NRb, in which Rb is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, cyano, or NO2;
each of R1 and R2, independently, is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, halo, cyano, nitro, ORc, OC(O)Rc, C(O)Rc, C(O)ORc, C(O)NRcRd, NRcRd, NHC(O)Rc, NHC(O)NRcRd, NHC(S)Rc, NHC(O)ORc, SO3Rc, or SO2NRcRd, in which each of Rc and Rd, independently, is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; or R1 and R2, together with the carbon atoms to which they are bonded, are cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl;
each of R3 and R4, independently, is H, halo, nitro, cyano, amino, hydroxy, alkoxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl;
A is arylene or heteroarylene;
B is O, S or NRe, in which Re is H, alkyl, alkenyl, or alkynyl;
C is O, S, alkylene, or NRf, in which Rf is H, alkyl, alkenyl, or alkynyl; or B and C, together with the carbon atom to which they are bonded, are heterocycloalkyl or heterocycloalkenyl;
D is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; or C and D together are heterocycloalkyl, heterocycloalkenyl, aryl or heteroaryl; and
n is 0, 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X1 is O or NH and X2 is CR2.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is H, alkyl, alkynyl, aryl, or heteroaryl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein Z is O and each of B and C is NH.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is phenyl optionally substituted with hydroxy or alkoxy.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R2 is H, alkyl, alkynyl, halo, aryl, or heteroaryl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein Y is NH and n is 2.

### Claim 8 (depends on 7)

The compound of claim 7, wherein A is phenyl; D is alkyl, aryl, heteroaryl, or cycloalkyl; and each of R3 and R4 is H.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is H, alkyl, alkynyl, aryl, or heteroaryl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is phenyl optionally substituted with hydroxy or alkoxy.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R2 is H, alkyl, alkynyl, halo, aryl, or heteroaryl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R2 is H, halo, or phenyl optionally substituted with hydroxy, alkoxy, or acylamino.

### Claim 13 (depends on 1)

The compound of claim 1, wherein Z is O and each of B and C is NH.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is phenyl optionally substituted with hydroxy or alkoxy.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R2 is H, halo, or phenyl optionally substituted with hydroxy, alkoxy, or acylamino.

### Claim 16 (depends on 1)

The compound of claim 1, wherein X1 is CR2 and X2 is O or NH.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R1 and R2, together with the carbon atoms to which they are bonded, are cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl.

### Claim 18

A compound of formula (I):
wherein
one of the two bonds is a single bond and the other is a double bond;
X1 is S and X2 is CR2, or X1 is CR2 and X2 is S;
each of Y and Z, independently, is O, S, or NRb, in which Rb is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, or cyano;
each of R1 and R2, independently, is alkynyl, aryl, heteroaryl, NRcRd, NHC(O)Rc, NHC(O)NRcRd, or NHC(S)Rc, in which each of Rc and Rd, independently, is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; or R1 and R2, together with the carbon atoms to which they are bonded, are cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl;
each of R3 and R4, independently, is H, halo, nitro, cyano, amino, hydroxy, alkoxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl;
A is arylene or heteroarylene;
B is O, S or NRe, in which Re is H, alkyl, alkenyl, or alkynyl;
C is O, S, alkylene, or NRf, in which Rf is H, alkyl, alkenyl, or alkynyl; or B and C, together with the carbon atom to which they are bonded, are heterocycloalkyl or heterocycloalkenyl;
D is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; or C and D together are heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl; and
n is 0, 1, 2, 3, or 4.

### Claim 19 (depends on 18)

The compound of claim 18, wherein X1 is S and X2 is CR2.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R1 and R2, together with the carbon atoms to which they are bonded, are cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein Z is O and each of B and C is NH.

### Claim 22 (depends on 21)

The compound of claim 21, wherein Y is NH and n is 2.

### Claim 23 (depends on 22)

The compound of claim 22, wherein A is phenyl; D is alkyl, aryl, heteroaryl, or cycloalkyl; and each of R3 and R4 is H.

### Claim 24 (depends on 23)

The compound of claim 23, wherein R1 and R2, together with the carbon atoms to which they are bonded, are cyclohexenyl.

### Claim 25 (depends on 19)

The compound of claim 19, wherein Z is O and each of B and C is NH.

### Claim 26 (depends on 25)

The compound of claim 25, wherein one of R1 and R2 is alkynyl optionally substituted with alkyl, alkylamino, or amido, and the other is aryl or heteroaryl.

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is one of Compounds 6, 24, 58, 79, 82, 206, 209, 256, and 258.

### Claim 28 (depends on 18)

The compound of claim 18, wherein the compound is Compound 42.

### Claim 29 (depends on 1)

A method for inhibiting the activity of a protein kinase, comprising contacting a cell expressing the protein kinase with an effective amount of a compound of claim 1.

### Claim 30 (depends on 29)

The method of claim 29, wherein the protein kinase is Aurora kinase.

### Claim 31 (depends on 18)

A method for inhibiting the activity of a protein kinase, comprising contacting a cell expressing the protein kinase with an effective amount of a compound of claim 18.

### Claim 32 (depends on 31)

The method of claim 31, wherein the protein kinase is Aurora kinase.

### Claim 33 (depends on 1)

A method for treating a protein kinase-mediated disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

### Claim 34 (depends on 33)

The method of claim 33, wherein the protein kinase-mediated disease is cancer.

### Claim 35 (depends on 18)

A method for treating a protein kinase-mediated disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 18.

### Claim 36 (depends on 35)

The method of claim 35, wherein the protein kinase-mediated disease is cancer.

### Claim 37 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 38 (depends on 18)

A pharmaceutical composition, comprising a compound of claim 18 and a pharmaceutically acceptable carrier.
